Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

Conditions: Epilepsies, Myoclonic, Drug Resistant Epilepsy

Sex: All

Ages: 2 Years – N/A

Sponsor: Eisai Inc.

Location: University of Alabama at Birmingham Birmingham Alabama

Summary

The primary purpose of this study is to provide continued access of lorcaserin to participants with Dravet syndrome and other refractory epilepsies.

Eligibility Criteria

Inclusion Criteria: 1. Confirmed diagnosis of Dravet syndrome (according to Recommendation from a North American Consensus Panel, 2017) or other refractory epilepsy (per the judgment of the treating physician) 2. Male or female, age at least 2 years at the time of informed consent 3. Currently treated with lorcaserin, that the treatment is for Dravet syndrome or other refractory epilepsies, and the treatment was initiated before 13 Feb 2020; or has completed Study E2023-A001-304 4. Has a clinical benefit from lorcaserin in the opinion of the treating physician Exclusion Criteria: None

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04457687). StuddyBuddy aggregates publicly available trial information.